India, Dec. 19 -- Pfizer India and Cipla Limited have announced a partnership where Cipla will exclusively market and distribute four brands of Pfizer in India.

Under the agreement, Cipla now has the sole right to market, distribute and sell the cough syrup Corex Dx and Corex LS, the non-steroidal anti-inflammatory drug (NSAID) Dolonex, the proton pump inhibitor (PPI) Neksium and the oral antibiotic Dalacin C in India. Pfizer will continue to manufacture, source and supply these medicines to Cipla for India.

Dalacin C is a part of Pfizer Products India Pvt. Ltd;Corex Dx; Corex LS, Dolonex and Neksium are a part of Pfizer Ltd.

Meenakshi Nevatia, Country President, Pfizer India, said,"WithPfizer's legacy ofbreakthroughs,qualityand innova...